grant
Targeting EZH2 in advanced prostate cancer
NIHUS FederalResearch GrantFY2026Amino Acid MotifsAndrogen AntagonistsAndrogen ReceptorAnti-AndrogenAnti-Androgen AgentsB-MYBBMYBBindingCDK2CDK2 geneCUT&RUNCancer GenesCancer PatientCancer TreatmentCancer-Promoting GeneCancersCatalytic CoreCatalytic DomainCatalytic RegionCatalytic SiteCatalytic SubunitCell Communication and SignalingCell Division Kinase 2Cell LineCell SignalingCellLineChromatinCleavage Targets and Release Using NucleaseCleavage Under Targets and Release Using NucleaseClinicClinical TrialsCombined Modality TherapyComplexCyclin-Dependent Kinase 2DataDevelopmentDiseaseDisorderDissectionDoseDrug TargetingE1A Binding Protein p300EP300EP300 geneEnhancersEvaluationFDA approvedFutureGene ActivationGene Down-RegulationGeneHomologGenesGenomic approachGoalsHeterograftHeterologous TransplantationHistonesHomologHomologous GeneHomologueIn VitroIntracellular Communication and SignalingKAT3BKnock-outKnockoutL-LysineLysineMGC15600MYBL2MYBL2 geneMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatingModelingMolecular InteractionMultimodal TherapyMultimodal TreatmentOncogene ActivationOncogene ProductsOncogene ProteinsOncogenesOncogenesisOncogenicOncoproteinsOrganoidsPARP InhibitorPARP-1 inhibitorPARPiPDX modelPathway interactionsPatient derived xenograftPatientsPhenotypePoly QPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPolycombPre-Clinical ModelPreclinical ModelsProstateProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate GlandProstate malignancyProstatic GlandProtacProtein MotifsProtein RegionProteolysis targeting chimericPublishingRNA SeqRNA sequencingRNAseqRegulatory PathwayReportingRepressionResearchResistanceRoleSignal TransductionSignal Transduction SystemsSignalingSiteSolidStrains Cell LinesTechnologyTerminal DiseaseTerminal IllnessTherapeuticTherapeutic EffectTransactivationTranscription RepressionTransforming GenesTranslatingVariantVariationWorkXenograftXenograft procedureXenotransplantationadvanced prostate cancerandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen inhibitorandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate canceranti-cancer therapybiological signal transductioncancer therapycancer-directed therapycastration resistant CaPcastration resistant PCacastration resistant prostate cancerclinical relevanceclinically relevantcofactorcombination therapycombined modality treatmentcombined treatmentcultured cell linedesigndesigningdetermine efficacydevelop therapydevelopmentaleffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacygene repressiongenomic effortgenomic strategyhistone H3 methyltransferasehistone acetyltransferase p300histone methylasehistone methylationhistone methyltransferasehormone refractory prostate cancerimprovedin vivoinhibitorinnovateinnovationinnovativeinsightintervention developmentknock-downknockdownleukemiamalignancymulti-modal therapymulti-modal treatmentneoplasm/cancernew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel lead compoundnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachp300pathwaypatient derived xenograft modelpolyQpolyglutaminepolyglycinepolyglycine IIprogramsprostate cancer cellprostate cancer cell lineprostate cancer modelprostate cancer resistant to androgenprostate cancer treatmentprostate tumor cellprostate tumor modelproteolysis targeting chimaeraproteolysis targeting chimeraresistantsmall moleculesocial rolestandard carestandard treatmentterminal declinetherapeutically effectivetherapy developmenttrans-activationtranscriptome sequencingtranscriptomic sequencingtreatment developmenttreatment strategytumortumorigenesisxeno-transplantxeno-transplantation
Description preview
PROJECT SUMMARY/ABSTRACT
Standard treatment of prostate cancer (PCa) with anti-androgen agents fails due to development of therapy
resistance and castration-resistant prostate cancer (CRPC), a terminal disease. Enhancer of Zeste Homolog 2
(EZH2), a histone methyltransferase and catalytic subunit of Polycomb Repressive Complex 2 (PRC2), and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click